Phase 1b data from a trial that assessed magrolimab with AZA for frontline treatment in patients with untreated AML ineligible for intensive chemotherapy revealed a CR of 31.9% and median OS of 9.8 months in the TP53-mutant group [115]. The gene discussed is TP53; the disease is acute myeloid leukemia.